CMN Weekly (2 June 2023) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jun. 2, 2023

#CRISPRMED24

Top picks

  • American and Japanese researchers have presented an encouraging dual stem cell tumour-targeting therapy for brain-metastatic melanoma. The novel treatment includes two stem cells, one of which is gene-edited to acquire resistance to oHSV and release beneficial immunomodulators via CRISPR-Cas9-mediated knockout of the nectin 1 receptor. The team found that local delivery of the novel therapy could treat both syngeneic and patient-derived humanised mouse models of brain-metastatic melanoma.
  • CRISPR-GRANT is a new cross-platform graphical analysis tool for high-throughput CRISPR-based genome editing evaluation. It offers a straightforward GUI by simple click-and-run for genome editing analysis of single or pooled amplicons and one-step analysis for whole-genome sequencing without data pre-processing, making it ideal for novice lab scientists. CRISPR-GRANT is a valuable addition to the current CRISPR toolkits, significantly lowering the barrier for wet-lab researchers to conduct indel analysis from large NGS datasets.

Research

Industry

Detection

Reviews and commentaries

Meetings and webinars

News from CRISPR Medicine News

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (2 June 2023) - Your Weekly CRISPR Medicine News
News: CMN Weekly (2 June 2023) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine